^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 inhibitor

    Related drugs:
    9d
    CA-4948 102: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1/2, N=366, Suspended, Curis, Inc. | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • SF3B1 (Splicing Factor 3b Subunit 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    FLT3 mutation • SF3B1 mutation
    |
    Venclexta (venetoclax) • emavusertib (CA-4948)
    10d
    CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies (2025-523600-68-00)
    P1/2, N=40, Not yet recruiting, Curis Inc.
    New P1/2 trial
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    1m
    CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax (2023-505828-58-00)
    P1, N=24, Active, not recruiting, Curis Inc. | -> Active, not recruiting | Phase classification: PN/A --> P1
    Enrollment closed • Phase classification
    |
    Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
    1m
    IRAK4: A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P1, N=28, Recruiting, AstraZeneca
    New P1 trial
    |
    metformin
    1m
    Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) (clinicaltrials.gov)
    P2, N=20, Terminated, Gilead Sciences | Active, not recruiting --> Terminated; Sponsor Decision
    Trial termination
    1m
    D7860C00006: A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease (2025-520473-40-00)
    P1/2, N=314, Recruiting, AstraZeneca AB
    New P1/2 trial
    1m
    D7860C00005: A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus (2025-522551-25-00)
    P1, N=28, Recruiting, AstraZeneca AB
    New P1 trial
    |
    metformin
    1m
    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies (clinicaltrials.gov)
    P2, N=108, Recruiting, Curis, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    2ms
    Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting | N=33 --> 20 | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Aug 2025 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    3ms
    Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=150, Recruiting, Lomond Therapeutics Holdings, Inc. | N=60 --> 150
    Enrollment change
    4ms
    CTN-03208-1: Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=112, Completed, Lomond Therapeutics Holdings, Inc. | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    itraconazole
    4ms
    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Curis, Inc.
    New P2 trial
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)